London's Exogenous Surfactant Study for COVID19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

October 6, 2021

Conditions
ARDS, HumanCOVID-19
Interventions
DRUG

Bovine Lipid Extract Surfactant

BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.

Trial Locations (2)

N6A 5A5

London Health Sciences Centre - University Hospital, London

Unknown

Victoria Hospital, London

Sponsors
All Listed Sponsors
collaborator

London Health Sciences Centre

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER